All'ambasciata d'Italia a Londra è stato presentato il libro 'Il regno fragile. Le difficoltà della Corona, gli effetti della Brexit, la svolta laburista' (People) di Tiziana Prezzo, corrispondente ...
Tiziana is currently conducting clinical trials using intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis. Manufacturing of clinical supplies for a Phase 1 study is anticipated to be completed in 4Q 2022.
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. BOSTON, MA, – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)...
Our Company Tiziana Life Sciences is a NASDAQ listed (NASDAQ:TLSA) clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and neuroinflammatory. Our clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer’s, and ALS. Tiziana is led by a team of highly qualified executives with extensive ...
Tiziana Life Sciences is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness.
Mr Cerrone is the Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA technology; Chairman and Founder of Tiziana Life Sciences plc (AIM: TILS) an oncology focused therapeutics company; Chairman and Co-Founder of Rasna Therapeutics Limited, a company focused on ...
BOSTON, MA, – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies today announced that that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501, and related assets (together “TZLS-501”) via a spinout into a separate publicly ...